Global Meningococcal Vaccines Market Is Expected To Reach Around USD 8,295 Million By 2025

Zion Market Research has published a new report titled “Meningococcal Vaccines Market By Type (Combination Vaccines, Polysaccharide Vaccines, Conjugate Vaccines, and Men B Vaccines) and By End-User (Hospital Pharmacies, Retail Pharmacies, and Others): Global Industry Perspective, Comprehensive Analysis, and Forecast, 2018–2025”. According to the report, the global meningococcal vaccines market was USD 3,833 million in 2018 and is expected to generate around USD 8,295 million by 2025, at a CAGR of around 11.73 % between 2019 and 2025.

Meningococcal vaccine treats meningitidis that is caused by bacteria N. These vaccines are administered via injections. In nations with low illness danger, they suggest immunizing high-risk groups. Generally, meningococcal vaccines are secure, but some individuals may feel pain and redness at the injection site.

Browse the full “Meningococcal Vaccines Market By Type (Combination Vaccines, Polysaccharide Vaccines, Conjugate Vaccines, and Men B Vaccines) and By End-User (Hospital Pharmacies, Retail Pharmacies, and Others): Global Industry Perspective, Comprehensive Analysis, and Forecast, 2018–2025” Report at https://www.zionmarketresearch.com/report/meningococcal-vaccines-market

Developing nations like Brazil, Russia, India, China, and South Africa are progressively engaged in improvising and expanding their health infrastructure along with investing heavily in innovation in health, progressively impacting the health procedures worldwide. Thus, to develop innovative health technologies, the Indian government is increasingly investing in the early phase of different research and development projects. Therefore, high-quality, low-cost vaccines produced by developing countries are likely to drive the meningococcal vaccines market. Furthermore, rising awareness about the meningococcal vaccines is also fuelling the meningococcal vaccines market development.

The meningococcal vaccines market is fragmented into type and end-user. Based on type, the market is classified into combination (MenHibrix and Menitorix), polysaccharide (NmVac4, Mencevax, Menomune, and others), conjugate (Menjugate, Nimenrix, Menveo, Menactra, NeisVac-C, MenAfriVac, Meningitec, and NmVac4-DT), and Men B vaccines (Bexsero and Trumenba). Conjugate vaccines will witness decent growth over the estimated timeframe, owing to the proximity of highly overlooked requirements and the lack of elective vaccine accessibility. MPSV4 is the primary antibody asserted to be used in people aged over 55 as well as 2 to 55 years. Novartis created Baxsero, an affirmed conjugate antibody, which has shown value in meningitis treatment and is the first Serogroup B antibody, is to be incorporated in the inoculation program. The end-user segment is classified into hospital pharmacies, retail pharmacies, and others.

North America is anticipated to lead the meningococcal vaccines market worldwide, owing to the increasing public measures and prevention programs and research and growth projects by multiple regional producers. Group-B vaccines have been custom-made for particular epidemic strains and are widely used in Cuba, Brazil, New Zealand, France, Chile, and Norway. In developed nations like Australia, Canada, and certain European countries, the incidence of meningococcal illnesses decreased before the advent of the vaccine, which further accelerated the disease's decline. This is followed by the regions of Latin America and the Middle East and Africa. Due to low production costs and increased healthcare expenditure, the Asia Pacific region is anticipated to be the fastest-growing in the meningococcal vaccines market.

Some key players of the meningococcal vaccines market are Novartis International, Nuron Biotech, GlaxoSmithKline, Pfizer, Sanofi, JN-International Medical, Baxter International, Serum Institute of India, and Biomed.

This report segments the global meningococcal vaccines market into:

Global Meningococcal Vaccines Market: Type Analysis

• Combination Vaccines
  • Menhibrix
  • Menitorix
• Polysaccharide Vaccines
  • Nmvac4
  • Menomune
  • Mencevax
  • Others
• Conjugate Vaccines
  • Nimenrix
  • Menactra
  • Menveo
  • Menafrivac
  • Neisvac-C
  • Meningitec
  • Menjugate
  • Nmvac4-Dt
• Men B Vaccines
  • Bexsero
  • Trumenba

Global Meningococcal Vaccines Market: End-User Analysis

• Hospital Pharmacies
• Retail Pharmacies
• Others

Global Meningococcal Vaccines Market: Regional Analysis

• North America
  • The U.S.
• Europe
  • UK
  • France
  • Germany
• Asia Pacific
  • China
  • Japan
  • India
• Latin America
  • Brazil
• The Middle East and Africa

About Us:
Zion Market Research is an obligated company. We create futuristic, cutting-edge, informative reports ranging from industry reports, the company reports to country reports. We provide our clients not only with market statistics unveiled by avowed private publishers and public organizations but also with vogue and newest industry reports along with pre-eminent and niche company profiles. Our database of market research reports comprises a wide variety of reports from cardinal industries. Our database is been updated constantly in order to fulfill our clients with prompt and direct online access to our database. Keeping in mind the client’s needs, we have included expert insights on global industries, products, and market trends in this database. Last but not the least, we make it our duty to ensure the success of clients connected to us—after all—if you do well, a little of the light shines on us.

Contact Us:
Zion Market Research
244 Fifth Avenue, Suite N202
New York, 10001, United States
Tel: +49-322 210 92714
USA/Canada Toll-Free No.1-855-465-4651
Email: sales@zionmarketresearch.com
Website: https://www.zionmarketresearch.com